38 results about "Th2 cytokines" patented technology

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum, and reducing the level of Th2 cytokines and IgE in serum.

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

The present invention relates to a composition for preventing, alleviating or treating respiratory diseases, containing a Siraitia grosvenorii residual extract as an active ingredient. In an ovalbumin(OVA) induced asthma animal model, a Siraitia grosvenorii residual extract of the present invention has effects of reducing airway hypersensitivity, inhibiting inflammatory cells in bronchoalveolar lavage fluid and reducing Th2 cytokines (IL-4, IL-5 and IL-13) in bronchoalveolar lavage fluid, reducing inflammation and tissue damage in lung tissue, inhibiting airway smooth muscle contraction and airway inflammation, inhibiting the expression of IL-13, TARC, TNF-a, IL-17 and mucus gene MUC5AC in lung tissue, and reducing, in alveolar cells, ROS having increased because of fine dust.

The present invention provides methods and compositions comprising crotyl esters or crotyl ester derivatives for the treatment of cytopathic diseases. Cytopathic diseases can be caused by various means, for example, viral infection, such as HIV and AIDS, or the development of neoplastic lesions in mammalian subjects. The methods and compositions of the present invention are effective for inhibiting new HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, downregulating HIV receptors, and increasing Th1 cytokine expression , reducing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant tumor cells, remission induction, remission maintenance, use as a chemotherapeutic agent, and for alleviating the symptoms of cytopathic diseases and the opportunistic infections that accompany these diseases. The present invention provides additional compositions and methods employing crotyl esters or derivatives thereof in combination with at least one additional agent, such as an agent for a course of HAART, a therapeutic agent for treating opportunistic infections due to HIV, or is a chemotherapeutic agent to generate a more effective therapeutic tool against cytopathic diseases in mammalian subjects.